WebSep 4, 2024 · At a glance Several drugs are associated with a change in urine color including nitrofurantoin (brown), rifampin (red) and promethazine (blue/green). Answer Maxalt ( rizatriptan) has not been reported as causing a change in urine color, unfortunately. WebThe Side Effects and Interactions of Antituberculosis Drugs Antituberculosis drugs may produce side effects varying from unimportant to life-threatening. The side effects of drugs prescribed for a patient must be known, as well as whether it is …
Rifampin Side Effects: Common, Severe, Long Term
WebApr 13, 2024 · Rifampin is a medication used in the management and treatment of various mycobacterial and gram-positive bacterial infections. ... Dose-dependent side effects include orange discoloration of body fluids like; tears (which can stain the patient's contact lenses), sweat, saliva, urine, and feces due to its excretion in these fluids, and ... WebPersistent weakness, fatigue, fever, or abdominal tenderness Easy bruising or bleeding Blurred vision or changed vision *Patients taking rifampin (RIF) or rifapentine (RPT) … eberron ships
National Center for Biotechnology Information
WebRIFAMPIN You have been given medicine to treat your latent TB infection. You do not have TB disease and cannot spread TB to others. This medicine will help you PREVENT getting … WebApr 1, 2024 · Rifampin will cause urine, saliva, sputum, sweat, teeth, and tears to turn a reddish-orange to reddish-brown color. This is to be expected while you are using this medicine. This effect may also cause soft contact lenses to become permanently … Rifampin will cause urine, saliva, sputum, sweat, teeth, and tears to turn a reddish … If you are taking itraconazole, do not use rifampin 2 weeks before and during … WebDiscoloured urine on rifampicin. ... sweat and urine may become orange coloured by oral rifampicin. Contact lenses may be permanently stained. This effect is usually mild and self-limiting. Cutaneous adverse reactions. ... Angelova I. Rifampin in dermatology. Clin Dermatol. 2003;21(1):50–5. doi: 10.1016/s0738-081x(02)00328-0. eberron summary